Trials / Conditions / Obesity or Overweight

Obesity or Overweight

16 registered clinical trials studyying Obesity or Overweight — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Di NCT07351058	Hoffmann-La Roche	Phase 3
Recruiting	A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type NCT07351045	Hoffmann-La Roche	Phase 3
Recruiting	Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection NCT07128888	Gan & Lee Pharmaceuticals.	Phase 1
Active Not Recruiting	A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least NCT07081958	Hoffmann-La Roche	Phase 2
Recruiting	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Dise NCT06937099	Eli Lilly and Company	Phase 3
Recruiting	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Act NCT06937086	Eli Lilly and Company	Phase 3
Completed	A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Me NCT06988553	Eccogene	Phase 1
Active Not Recruiting	A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo NCT06862791	AstraZeneca	Phase 2
Active Not Recruiting	Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight NCT06867718	Regor Pharmaceuticals Inc.	Phase 2
Completed	Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbid NCT06579092	AstraZeneca	Phase 2
Completed	A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity NCT06595238	AstraZeneca	Phase 2
Completed	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight NCT05996848	Novo Nordisk A/S	Phase 3
Completed	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight NCT05813925	Novo Nordisk A/S	Phase 3
Completed	A Study of IBI362 in Participants With Obesity or Overweight NCT05607680	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3
Completed	A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Sett NCT05153590	Novo Nordisk A/S	—
Completed	Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican NCT03629301	Universidad de Sonora	N/A